Massive hemorrhage management – a best evidence topic report

Abstract

IntroductionMassive hemorrhage remains a major cause of potentially preventable deaths. Better control of bleeding could improve survival rates by 10%–20%. Transfusion intervention concepts have been formulated in order to minimize acute traumatic coagulopathy. These interventions still have not been standardized and vary among medical centers.Materials and MethodsBased on a literature search using free term keywords and Medical Subject Heading (MeSH) index, we analyzed published articles addressing massive hemorrhage, component therapy, fresh whole blood, and fibrinogen from the year 2000 onward, in journals with impact factor >1.000, in Medline, PubMed, and Google Scholar. The evidence was grouped into topics including laboratory testing and transfusion interventions/viscoelastic assays vs standard laboratory tests, the effect of component therapy on patient outcome, the effect of warm fresh whole blood on patient outcome, and the effects of fibrinogen in severe bleeding. The obtained information was compared, evaluated, confronted, and was focused on to present an adequate and individual-based massive hemorrhage management approach.ResultsViscoelastic whole-blood assays are superior to standard coagulation blood tests for the identification of coagulopathy and for guiding decisions on appropriate therapy in patients with severe bleeding. Replacement of plasma, red blood cells, platelets, and fibrinogen in a ratio of 1:1:1:1 has appeared to be the best substitution for lost whole blood. There is no evidence that cryoprecipitate improves the outcome of patients with severe hemorrhage. Current literature promotes the transfusion of warm fresh whole blood, which seems to be superior to the component therapy in certain clinical situations. Some authors recommend that fibrinogen and other coagulation factors be administered according to the viscoelastic attributes of the blood clot.ConclusionThis best-evidence topic report brings comprehensive information about massive hemorrhage management.

Rotational Thromboelastometry Helps to Reduce Blood Product Consumption in Critically Ill Patients during Small Surgical Procedures at the Intensive Care Unit - a Retrospective Clinical Analysis and Literature Search

“…According to the literature, these data are in accordance with those of other authors who found ROTEM to be effective in reducing FFP and PC consumption in a cardiac intensive care unit [14], during liver transplantation [15], and also in management of traumatic bleeding [16] and massive hemorrhage management [17]. This approach to coagulation assessment protects patients from unnecessary FFP and PC administration which are generally connected with increased morbidity and mortality.…”

Direct thrombolysis of multiple thrombi in both right and left heart atrium in a patient on extracorporeal membrane oxygenation support following urgent double-lung transplantation: a case report

“… 7 Following other authors’ recommendations, we followed a restrictive blood transfusion strategy. 19 The fibrinogen level <1.5 g/L during thrombolysis was not associated with an increased bleeding risk. 16 , 20 It is well documented that larger doses as well as increased duration of thrombolysis are associated with an increased risk of bleeding.…”

The bloody mess of red blood cell transfusion

“…In the setting of acute uncontrollable haemorrhage, RBC transfusion frequently saves lives [ 16 ]. This common understanding is based on strong clinical experience, albeit on weak study evidence, because denying transfusions in a life-threatening condition for the sake of a trial would be undoubtedly unethical.…”